TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Laboratory-Confirmed Rotavirus Hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: ED Visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to progression free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Changes in office blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Transseptal time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Left atrial dwell time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PVI ablation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ablation time per pulmonary vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Immediate Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Delayed Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Processing Speed: Colour Trails 1 and 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Mindfulness Awareness and Attention Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Late cytomegalovirus infection by plasma PCR positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Parasite reappearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hospitalization during follow-up
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time to recurrent life-threatening haemoptysis
Endpoint domain: Mortality/survival
Primary endpoint: Clinical assessment of suicidality per the suicidality rating scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Endotoxin rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angles of ocular deviations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events Evaluation
Endpoint domain: Adverse events/effects
Primary endpoint: Patient discomfort with the two immobilization masks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mask preference
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Changes in VO2peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sleep architecture
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in neuropsychological performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Level of frailty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psoriasis Area and Severity Index (PASI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of SARS-CoV-2 eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Progression-free survival at one year
Endpoint domain: Mortality/survival
Primary endpoint: Change in diagnostic status at post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in child/adolescent problem areas at post-treatment (CBCL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in clinical global impression during treatment course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Improvement in COVID-19 Clinical Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported sleep duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Five-Year Relapse-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: growth rate of children with osteogenesis imperfecta
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total bone mineral content of children with osteogenesis imperfecta
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in C-peptide AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With a Postoperative Intra-abdominal Abscess
Endpoint domain: Adverse events/effects
Primary endpoint: Blood pressure (mothers)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood pressure (children)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dosage of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any Adverse Event (AE), Serious Adverse Event (SAE) or Death
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Fasting Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of post-operative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute bioavailability of AZD9977
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative amount of AZD9977 excreted (CumAe)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative amount of AZD9977 excreted as a percentage of the administered dose (CumFe)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Score Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in drinks per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of reverse seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reinforcing Value of Food
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Delay of Gratification
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 24 hour dietary recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Go/no-go task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Glycemic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Drug-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Canadian Occupational Performance Measure Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Goal Attainment Scaling
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Manual Ability Classification System Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in symptoms of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area Under the Plasma Concentration-time Curve of MK-3866 From Time Zero to Infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration of MK-3866 (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Clearance of MK-3866 (CL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of tacrolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Postoperative Urinary Retention (POUR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in JunD/AP-1 signaling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: App usage ratio during intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma IL-6 concentration (All Participants)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in plasma IL-6 concentration (HIV-Infected Participants)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of patients lost to follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of treatment related adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Monocyte VDR Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline of pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates (complete response, partial response, no change, progressive disease)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Teething pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematological Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: asthma-specific quality-of-life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Lipid Panel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patency of treated target site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Calcium in aortic valve and coronary arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in functional and structural connectivity relationships of brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in biomarkers of brain alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 6 Minute Walk Test Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction to fetal expulsion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in Wound Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Efficacy of letrozole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Selection and review of cases of Synovial Chondrosarcoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Vaccine immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the Artificially-Intelligent Stethoscope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in fasting and postprandial triglyceride concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Sickle Cell Disease leg ulcer wound pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate and extent of leg ulcer wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Incidence of Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Incidence of Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants that complete the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: quality of CCC asthma policy
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: limbic activation by ultra-brief cocaine cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Implant revision rate
Endpoint domain: Adverse events/effects
Primary endpoint: Radiographic assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: long term safety and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: long term effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of participants with osseous consolidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Return to Baseline Physical Function Based on the Barthel Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aqueous Humour Concentration of Levofloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aqueous Humour Concentration of Dexamethasone 21-phosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aqueous Humour Concentration of Dexamethasone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of HSV1716 treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Myocardial Energetic Efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in global longitudinal strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of Pain in the Lower Extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in proportion of dispensed doses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Able to be Weaned Off All Third-Line Agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FeNO Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dental erosion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-pneumococcal Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in ambulatory systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in ambulatory diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in ambulatory mean blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 28-day mortality after admission
Endpoint domain: Mortality/survival
Primary endpoint: ICU mortality, n (%)
Endpoint domain: Mortality/survival
Primary endpoint: Change in malaria annual parasite incidence (API)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pain and analgesia score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Plasma PK parameters (AUC, Cmax, CL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant attachment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of prolonged postoperative ileus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: decrease in insulin requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decrease in incidence of hypoglycemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of LMP744
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients experiencing symptoms at 12 months postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sputum cytokine mRNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Optimal biological dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total CVD incidence
Endpoint domain: Mortality/survival
Primary endpoint: Major DM complications (CHD, stroke, heart failure, ESRD)
Endpoint domain: Mortality/survival
Primary endpoint: Change in hemodynamic stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Target Lesion Revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pain at coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent pain at 4 months after surgery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to first post-operative rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Off Time as Measured by Patient Diary
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Off Time as Measured by Wireless Computer Monitoring System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in RSI and RFS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unnecessary consultations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical Global Impression - Improvement (CGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change in Liebowitz Social Anxiety Scale (LSAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difference in staging of sigmoid cancer on CT and MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Radiographic success - in volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic success - in density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects achieving a hematopoietic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Recommended dose
Endpoint domain: Physiological/clinical
Primary endpoint: PANSS-EC Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to the First Missed Dose
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cmax: Maximum Observed Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax: Time to Reach the Maximum Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Natural Killer cell activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mechano-chemical properties of urine proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of female subjects with spontaneous abortion
Endpoint domain: Mortality/survival
Primary endpoint: Number of female subjects giving still births
Endpoint domain: Mortality/survival
Primary endpoint: Number of infants with birth defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Severe RDS
Endpoint domain: Adverse events/effects
Primary endpoint: Changes of skin temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to Composite of All-Cause Mortality and Non-Fatal Cardiovascular Events
Endpoint domain: Mortality/survival
Primary endpoint: Combinations of genetic lesions that correlate with nodal metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Parent to Child Conflict Tactics Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in average daytime ambulatory systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concordance between surgical impression and post-operative imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary Catheterization Skill Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial fat deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in The Neuromuscular Gross Motor Outcome (GRO) scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hammersmith Functional Motor Scale Expanded (HFMSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Revised Hammersmith Scale (RHS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Clinical Response at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Clinical Remission at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Clinical Remission at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Clinical Remission at Week 104
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes